• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Innovative therapy for lung cancer: prophylaxis and therapy by intratracheal delivery of probiotics harboring immune checkpoint-blocking single-chain variable fragment

Research Project

Project/Area Number 19KK0208
Research Category

Fund for the Promotion of Joint International Research (Fostering Joint International Research (B))

Allocation TypeMulti-year Fund
Review Section Medium-sized Section 50:Oncology and related fields
Research InstitutionShinshu University

Principal Investigator

Sato Takashi  信州大学, 先鋭領域融合研究群バイオメディカル研究所, 特任教授 (70510436)

Co-Investigator(Kenkyū-buntansha) 下里 剛士  信州大学, 学術研究院農学系, 教授 (00467200)
荻田 佑  信州大学, 学術研究院農学系, 助教 (50738010)
重盛 駿  信州大学, 先鋭領域融合研究群バイオメディカル研究所, 助教(特定雇用) (90803487)
生井 楓  東北大学, 農学研究科, 特任助教 (60893857)
Project Period (FY) 2019-10-07 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
Fiscal Year 2022: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2021: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Keywords遺伝子組換え乳酸菌 / 肺がん / 免疫チェックポイント阻害 / 経気道治療 / 生物資源医薬 / 経気道的標的治療 / 肺癌
Outline of Research at the Start

本研究は、気道粘膜免疫を標的とする「微生物由来合成核酸の経気道治療の研究」と、「有用微生物である乳酸菌由来高分子・抗体医薬の経気道治療の研究」成果を基盤とし、免疫チェックポイント阻害作用を有する乳酸菌による肺癌発癌・進展予防効果を検証する内容である。本研究は、早期の臨床試験への導出を目的として、癌研究と治療開発で世界最先端の米国テキサス大学MDアンダーソンがんセンターとの国際共同研究として計画した。申請者が所属する信州大学の乳酸菌研究のエキスパートと若手研究者の参画に加えて、国際的に高い信頼と臨床導出の実績がある癌専門研究機関の参画により、早期に次世代治療として確立を目指す内容である。

Outline of Final Research Achievements

In this study, we constructed genetically modified lactic acid bacteria (gmLAB) that produce biologically active single chain variable fragment (scFv) specifically targeting immune checkpoint molecules. Of these, programmed cell death-ligand 1 (PDL1) scFv showed significant improvement in survival in both murine primary lung cancer and metastatic lung tumor models by intranasal administration. Repeated administration of gmLAB was well tolerated, and no apparent adverse events were seen. These results would propose a new therapeutic strategy for malignant lung diseases by administering intranasally with gmLAB. Further trial was planned to explore the combined use of immune checkpoint inhibiting gmLAB with molecular-target drugs for lung cancer harboring oncogenic driver mutation.

Academic Significance and Societal Importance of the Research Achievements

本研究成果の学術的意義は、肺癌に対する治療戦略として乳酸菌という生物資源を用いた創薬基盤ならびに新規投与経路の開拓にある。高い費用対効果と治療忍容性が期待される点でも社会的意義は大きい。将来的には、遺伝子変異陽性肺癌に対する分子標的医薬と乳酸菌由来低分子抗体医薬の合剤による経気道治療の概念も提唱しうる研究成果となった。コロナ禍のなかで、研究成果を米国並びに欧州の国際学会での発表につなげ、さらに国際ワークショップを開催して海外日本人研究者との連携構築につながる機会を得たことは大きな意義をもつ。今後の国際共同研究の推進と、本分野をリードする研究成果の創出につながる支援が得られたと考える。

Report

(6 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • 2020 Research-status Report
  • 2019 Research-status Report
  • Research Products

    (34 results)

All 2024 2023 2022 2021 2020 2019 Other

All Int'l Joint Research (5 results) Journal Article (16 results) (of which Peer Reviewed: 13 results,  Open Access: 10 results) Presentation (9 results) (of which Int'l Joint Research: 7 results,  Invited: 2 results) Book (1 results) Remarks (1 results) Patent(Industrial Property Rights) (1 results) (of which Overseas: 1 results) Funded Workshop (1 results)

  • [Int'l Joint Research] テキサス大学(米国)

    • Related Report
      2023 Annual Research Report
  • [Int'l Joint Research] MD Anderson Cancer Center(米国)

    • Related Report
      2022 Research-status Report
  • [Int'l Joint Research] テキサス大学(米国)

    • Related Report
      2021 Research-status Report
  • [Int'l Joint Research] テキサス大学MDアンダーソンがんセンター(米国)

    • Related Report
      2020 Research-status Report
  • [Int'l Joint Research] テキサス大学MDアンダーソンがんセンター(米国)

    • Related Report
      2019 Research-status Report
  • [Journal Article] 組換え乳酸菌による肺がん免疫治療2024

    • Author(s)
      佐藤 隆
    • Journal Title

      Precision Medicine

      Volume: 7 Pages: 554-558

    • Related Report
      2023 Annual Research Report
  • [Journal Article] 組換え乳酸菌による医薬・ワクチン開発2024

    • Author(s)
      佐藤 隆
    • Journal Title

      BIO Clinica

      Volume: 39 Pages: 531-535

    • Related Report
      2023 Annual Research Report
  • [Journal Article] Development of a Single-Chain Fragment Variable that Binds to the SARS-CoV-2 Spike Protein Produced by Genetically Modified Lactic Acid Bacteria2024

    • Author(s)
      Oshima Suzuka、Namai Fu、Sato Takashi、Shimosato Takeshi
    • Journal Title

      Molecular Biotechnology

      Volume: 66 Issue: 1 Pages: 151-160

    • DOI

      10.1007/s12033-023-00741-y

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] 組換え乳酸菌による肺癌免疫治療2023

    • Author(s)
      佐藤 隆
    • Journal Title

      BIO Clinica

      Volume: 38 Pages: 638-642

    • Related Report
      2023 Annual Research Report
  • [Journal Article] Oral administration of <scp><i>Brevibacterium linens</i></scp> from washed cheese increases the proportions of short‐chain fatty acid‐producing bacteria and lactobacilli in the gut microbiota of mice2023

    • Author(s)
      Murakami Aito、Toyomoto Koharu、Namai Fu、Sato Takashi、Fujii Tadashi、Tochio Takumi、Shimosato Takeshi
    • Journal Title

      Animal Science Journal

      Volume: 94 Issue: 1

    • DOI

      10.1111/asj.13905

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Development of fluorescence-labeled antibody for immune checkpoint inhibitor using engineered probiotics2023

    • Author(s)
      Namai Fu、Sumiya Shunsuke、Nomura Natsumi、Sato Takashi、Shimosato Takeshi
    • Journal Title

      AMB Express

      Volume: 13 Issue: 1 Pages: 4-4

    • DOI

      10.1186/s13568-023-01509-y

    • Related Report
      2023 Annual Research Report 2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Free feeding of CpG-oligodeoxynucleotide particles prophylactically attenuates allergic airway inflammation and hyperresponsiveness in mice2021

    • Author(s)
      Okajima, T., Shigemori, S., Namai, F., Ogita, T., Sato, T. & Shimosato, T.
    • Journal Title

      Frontiers in Immunology

      Volume: 12 Pages: 738041-738041

    • DOI

      10.3389/fimmu.2021.738041

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Oral administration of Flavonifractor plautii, a bacteria increased with green tea consumption, promotes recovery from acute colitis in mice via suppression of IL-172021

    • Author(s)
      Ayane Mikami, Tasuku Ogita, Fu Namai, Suguru Shigemori, Takashi Sato, Takeshi Shimosato
    • Journal Title

      Frontiers in Nutrition

      Volume: 7 Pages: 610946-610946

    • DOI

      10.3389/fnut.2020.610946

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Construction of Genetically Modified Lactococcus lactis Producing Anti-human-CTLA-4 Single-Chain Fragment Variable2020

    • Author(s)
      Namai Fu、Murakami Aito、Ueda Asami、Tsukagoshi Masami、Shigemori Suguru、Ogita Tasuku、Sato Takashi、Shimosato Takeshi
    • Journal Title

      Molecular Biotechnology

      Volume: 62 Issue: 11-12 Pages: 572-579

    • DOI

      10.1007/s12033-020-00274-8

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Nasally Administered Lactococcus lactis Secreting Heme Oxygenase-1 Attenuates Murine Emphysema2020

    • Author(s)
      Yumoto Kentaro、Sato Takashi、Nakashima Kentaro、Namai Fu、Shigemori Suguru、Shimosato Takeshi、Kaneko Takeshi
    • Journal Title

      Antioxidants

      Volume: 9 Issue: 11 Pages: 1049-1049

    • DOI

      10.3390/antiox9111049

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Construction of genetically modified Lactococcus lactis that produces bioactive anti-interleukin-4 single-chain fragment variable2020

    • Author(s)
      Namai Fu、Shigemori Suguru、Ogita Tasuku、Sato Takashi、Shimosato Takeshi
    • Journal Title

      Molecular Biology Reports

      Volume: 47 Issue: 9 Pages: 7039-7047

    • DOI

      10.1007/s11033-020-05765-0

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Microbial therapeutics for acute colitis based on genetically modified Lactococcus lactis hypersecreting IL-1Ra in mice2020

    • Author(s)
      Namai Fu、Shigemori Suguru、Ogita Tasuku、Sato Takashi、Shimosato Takeshi
    • Journal Title

      Experimental & Molecular Medicine

      Volume: 52 Issue: 9 Pages: 1627-1636

    • DOI

      10.1038/s12276-020-00507-5

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Ribosome-Engineered Lacticaseibacillus rhamnosus Strain GG Exhibits Cell Surface Glyceraldehyde-3-Phosphate Dehydrogenase Accumulation and Enhanced Adhesion to Human Colonic Mucin2020

    • Author(s)
      Ishida Minori、Namai Fu、Shigemori Suguru、Kajikawa Shoko、Tsukagoshi Masami、Sato Takashi、Ogita Tasuku、Shimosato Takeshi
    • Journal Title

      Applied and Environmental Microbiology

      Volume: 86 Issue: 20

    • DOI

      10.1128/aem.01448-20

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Oral administration of Flavonifractor plautii attenuates inflammatory responses in obese adipose tissue2020

    • Author(s)
      Ayane Mikami, Tasuku Ogita, Fu Namai, Suguru Shigemori, Takashi Sato, Takeshi Shimosato
    • Journal Title

      Molecular Biology Reports

      Volume: 47 Issue: 9 Pages: 6717-6725

    • DOI

      10.1007/s11033-020-05727-6

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] The clinical significance of CXCL16 in the treatment of advanced non‐small cell lung cancer2020

    • Author(s)
      Shibata Yuji、Kobayashi Nobuaki、Sato Takashi、Nakashima Kentaro、Kaneko Takeshi
    • Journal Title

      Thoracic Cancer

      Volume: 11 Issue: 5 Pages: 1258-1264

    • DOI

      10.1111/1759-7714.13387

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Oral Administration of Flavonifractor plautii Strongly Suppresses Th2 Immune Responses in Mice2020

    • Author(s)
      Ogita Tasuku、Yamamoto Yoshinari、Mikami Ayane、Shigemori Suguru、Sato Takashi、Shimosato Takeshi
    • Journal Title

      Frontiers in Immunology

      Volume: 11 Pages: 379-379

    • DOI

      10.3389/fimmu.2020.00379

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] Microbial therapeutics for lung cancer based on immune-checkpoint inhibitory scFv-producing engineered lactic acid bacteria2023

    • Author(s)
      Fu Namai, Haruki Kitazawa, Takashi Sato, Takeshi Shimosato
    • Organizer
      FEMS (Federation of European Microbiological Societies) 2023
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Intranasal Administration of Genetically Modified Lactococcus Lactis Producing PD-L1 scFv Improves Survival in Lung Cancer Model Mice2023

    • Author(s)
      Natsumi Nomura, Fu Namai, Takashi Sato, Takeshi Shimosato
    • Organizer
      ATS (American Thoracic Society) 2023 International Conference
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Effect of Local Intratracheal Therapy Using Particleized Nintedanib in a Murine Model of Pulmonary Fibrosis2023

    • Author(s)
      Kaho Suzuki, Fu Namai, Natsumi Nomura, Yuichi Sato, Akihiro Kotsugai, Takeshi Shimosato, Takashi Sato
    • Organizer
      ATS (American Thoracic Society) 2023 International Conference
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Intranasal Administration of Genetically Modified Lactococcus Lactis Producing PD-L1scFv Improves Survival in Lung Cancer Model Mice2023

    • Author(s)
      Nomura N, Namai F, Sato T, Shimosato T
    • Organizer
      American Thoracic Society 2023 International Conference
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research
  • [Presentation] Intranasal-administrable microbial therapeutics for lung cancer based on immune- checkpoint inhibitory scFv-producing genetically modified lactic acid bacteria2023

    • Author(s)
      Namai F, Sato T, Shimosato T
    • Organizer
      Federation of European Microbiological Societies 2023
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research
  • [Presentation] Intratracheal therapy using oligodeoxynucleotides and/or genetically modified lactic acid bacteria-derived biological molecules2022

    • Author(s)
      Takashi Sato
    • Organizer
      Korean Society of Toxicology Spring International Symposium
    • Related Report
      2021 Research-status Report
    • Int'l Joint Research / Invited
  • [Presentation] 1.抗CTLA-4低分子抗体を産生するLactococcus lactis組換え体の構築2019

    • Author(s)
      村上愛斗, 生井楓, 上田麻未,重盛駿, 荻田佑, 佐藤隆, 下里剛士
    • Organizer
      2019酪農科学シンポジウム
    • Related Report
      2019 Research-status Report
  • [Presentation] 2.PD-1/PD-L1チェックポイントの阻害に働く乳酸菌組み換え体の構築と肺がんモデルマウスを用いた検証2019

    • Author(s)
      上田麻未,生井楓,村上愛斗,重盛駿,荻田佑,佐藤隆,下里剛士
    • Organizer
      2019酪農科学シンポジウム
    • Related Report
      2019 Research-status Report
  • [Presentation] Innovative therapy for lung cancer ~Intratracheal delivery of nanomicroparticles-incorporated immune checkpoint-blocking single-chain variable fragment~2019

    • Author(s)
      Sato T
    • Organizer
      NIH/NCI Symposium on Innate Immunity & Modulation of the Host Immune Response in Honor of the Career of Dr. Dennis Klinman
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research / Invited
  • [Book] A Compendium of Chronic Obstructive Pulmonary Disease-Intratracheally Therapeutic Option for COPD: A Potential Usage of the Therapeutic Microbe for Delivering Specific Protein to the Lungs2023

    • Author(s)
      Sato T and Shimosato T
    • Total Pages
      11
    • Publisher
      IntechOpen
    • ISBN
      9781803567686
    • Related Report
      2022 Research-status Report
  • [Remarks] New Treatment Modality for Lung Diseases

    • URL

      https://www.ingentaconnect.com/content/sil/impact/2019/00002019/00000003/art00022

    • Related Report
      2019 Research-status Report
  • [Patent(Industrial Property Rights)] 医薬組成物2020

    • Inventor(s)
      佐藤隆、下里剛士、森谷樹、森永匡彦、佐藤祐一、小番昭宏
    • Industrial Property Rights Holder
      佐藤隆、下里剛士、森谷樹、森永匡彦、佐藤祐一、小番昭宏
    • Industrial Property Rights Type
      特許
    • Filing Date
      2020
    • Related Report
      2019 Research-status Report
    • Overseas
  • [Funded Workshop] International workshop 2023 Inhaled Probiotic Therapy Next Era Therapeutic Modality for Lung Cancer2023

    • Related Report
      2023 Annual Research Report

URL: 

Published: 2019-10-10   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi